Table 1.

Inputs for simulation

Input		Effect Size	Reference
EFFECTIVENESS
LDL-C Lowering from statins		34% (95% CI: 20.4, 47.6)	(2, 25)
Beta-Coefficient, per mg/dL of LDL-C
	Stroke	0	(25)
	CHD Base Case	0.004 (SD 0.0006) 0.003 (SD 0.0006)	(26)
	CHD Low Sensitivity	0.001	(25)
	CHD High Sensitivity	0.007	(26)
COST
Medication Costs	Base Case	$5/30/days	(27)
	Low Sensitivity	$4/30 days	(29)
	High Sensitivity	$30/30 days	(29)
Physician Visit	1 every 4 years	$67	(31)
Lipid Panel		$19	(32)
Creatine Kinase	3 tests per myopathy case	$9.33	(32)
Hospitalization from stroke		$15,000	(18–20)
ADVERSE EFFECTS
Myopathy (events per statin- year)		0.001	(2)
Hemorrhagic Stroke (events per statin-year)		0.001	(2)
Time to recover from myopathy		2 Months	Clinical judgment
QALY Reduction of Myopathy	(musculoskeletal problems, severe)	0.606	(24)
QALY Reduction of Stroke	(moderate plus cognition problems)	0.312	(24)
GERIATRIC-SPECIFIC
ADVERSE EFFECTS
Statin Associated Disability	Base Case	0	Clinical judgment
Adjusted Life-Year Reduction due to Functional Limitation or Mild Cognitive Impairment	Sensitivity	0–0.01	Clinical judgment
Prevalence of Functional Limitation		32%	(33)
Disability Adjusted Life-Year Reduction of Functional Limitation		0.076	(24)
Prevalence of Mild Cognitive Impairment		25%	(34)
Disability Adjusted Life Year Reduction of Mild Cognitive Impairment		0.082	(24)
10-YEAR CVD RISK		>7.5% for all ≥75 years	(35)

Abbreviations: LDL-C = low-density lipoprotein cholesterol; CHD = CHD